INS and type 2 diabetes mellitus: Results from our study demonstrated that use of rtCGM was associated with reductions in HbA1c, average glucose and glycemic variability, with increases in %TIR and corresponding decreases in %TAR in T2D patients treated with either basal insulin and/or noninsulin therapy but not prandial or premised insulin.